ACC 2014: Conflicts in renal denervation, competition in valves

April 3, 2014 By Arezu Sarvestani Leave a Comment

The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

March 31, 2014 By Brad Perriello Leave a Comment

Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific‘s (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology’s annual meeting over the weekend.

ACC 2014 UPDATE: Reaction to Medtronic’s Symplicity renal denervation data

March 31, 2014 By Brad Perriello Leave a Comment

Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

ACC 2014: Sapien XT bests CoreValve in small head-to-head study

March 31, 2014 By Brad Perriello Leave a Comment

UPDATED March 31, 2014, with comment from Medtronic

ACC 2014: Medtronic details Symplicity renal denervation data

March 29, 2014 By Ingrid Mezo Leave a Comment

Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

ACC 2014: Medtronic can skip FDA panel on positive high-risk CoreValve data

March 29, 2014 By Brad Perriello Leave a Comment

Medtronic (NYSE:MDT) said today that the FDA will allow it to skip an advisory panel on high-risk patients for its CoreValve replacement heart valve, after data from a clinical study showed the transcatheter aortic heart implant is superior to open heart surgery.

Medtech gears up for Medtronic’s RDN trial results | MassDevice.com On Call

March 28, 2014 By Brad Perriello Leave a Comment

MASSDEVICE ON CALL — The medical device world will be watching intently this weekend as Medtronic (NYSE:MDT) releases data for the 1st time from a failed clinical trial of its Symplicity renal denervation device.

MASSDEVICE MEDICAL NETWORK

MASSDEVICE